Answer
In pooled studies of CARVYKTI (ciltacabtagene autoleucel), the most frequently reported grade 3 or higher infections were pneumonia, COVID-19 pneumonia and sepsis, each reported in at least 2% of patients.
Sources for this answer
- CARVYKTI 3.2 × 10^6 – 1 × 10^8 cells dispersion for infusionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.8 Undesirable effects · Version 6Document updated
Sources checked